MA44234A - Procédés de traitement ou de prévention de l'athérosclérose par administration d'un inhibiteur d'angptl3 - Google Patents

Procédés de traitement ou de prévention de l'athérosclérose par administration d'un inhibiteur d'angptl3

Info

Publication number
MA44234A
MA44234A MA044234A MA44234A MA44234A MA 44234 A MA44234 A MA 44234A MA 044234 A MA044234 A MA 044234A MA 44234 A MA44234 A MA 44234A MA 44234 A MA44234 A MA 44234A
Authority
MA
Morocco
Prior art keywords
atherosclerosis
administration
prevention
treatment
methods
Prior art date
Application number
MA044234A
Other languages
English (en)
Other versions
MA44234B1 (fr
Inventor
Jesper Gromada
Viktoria Gusarova
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA44234A publication Critical patent/MA44234A/fr
Publication of MA44234B1 publication Critical patent/MA44234B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA44234A 2016-02-17 2017-02-13 Procédés de traitement ou de prévention de l'athérosclérose par administration d'un inhibiteur d'angptl3 MA44234B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662296110P 2016-02-17 2016-02-17
PCT/US2017/017640 WO2017142832A1 (fr) 2016-02-17 2017-02-13 Procédés de traitement ou de prévention de l'athérosclérose par administration d'un inhibiteur d'angptl3

Publications (2)

Publication Number Publication Date
MA44234A true MA44234A (fr) 2018-12-26
MA44234B1 MA44234B1 (fr) 2023-10-31

Family

ID=58108756

Family Applications (1)

Application Number Title Priority Date Filing Date
MA44234A MA44234B1 (fr) 2016-02-17 2017-02-13 Procédés de traitement ou de prévention de l'athérosclérose par administration d'un inhibiteur d'angptl3

Country Status (25)

Country Link
US (3) US20170233466A1 (fr)
EP (2) EP4234013A3 (fr)
JP (3) JP7648335B2 (fr)
KR (1) KR102860143B1 (fr)
CN (1) CN108697797A (fr)
AU (1) AU2017219602C1 (fr)
CA (1) CA3014928A1 (fr)
DK (1) DK3416684T5 (fr)
EA (1) EA201891853A1 (fr)
ES (1) ES2951262T3 (fr)
FI (1) FI3416684T3 (fr)
HR (1) HRP20230992T1 (fr)
HU (1) HUE062709T2 (fr)
IL (1) IL260931B2 (fr)
LT (1) LT3416684T (fr)
MA (1) MA44234B1 (fr)
MD (1) MD3416684T2 (fr)
MX (1) MX2018009680A (fr)
PL (1) PL3416684T3 (fr)
PT (1) PT3416684T (fr)
RS (1) RS64476B1 (fr)
SI (1) SI3416684T1 (fr)
SM (1) SMT202300219T1 (fr)
WO (1) WO2017142832A1 (fr)
ZA (1) ZA201805058B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
MA43734A (fr) 2016-03-03 2018-11-28 Regeneron Pharma Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3
CN109096369B (zh) * 2018-09-10 2020-07-07 云南民族大学 一种特异性检测铜离子和硫离子的多肽、化学荧光传感器及其制备方法与应用
EP3880819A2 (fr) * 2018-11-13 2021-09-22 Lipigon Pharmaceuticals AB Oligonucléotides d'angptl4 influençant la régulation du métabolisme des acides gras
WO2020099525A2 (fr) * 2018-11-13 2020-05-22 Lipigon Pharmaceuticals Ab Oligonucléotides influençant la régulation du métabolisme des acides gras
WO2020099482A2 (fr) * 2018-11-13 2020-05-22 Lipigon Pharmaceuticals Ab Oligonucléotides d'angptl3 influençant la régulation du métabolisme des acides gras
US12559551B2 (en) 2019-05-24 2026-02-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ANGPTL3 antibodies
CN112062844B (zh) * 2019-06-10 2022-07-19 山东博安生物技术股份有限公司 抗angptl3抗体及其用途
US20220380425A1 (en) * 2019-07-04 2022-12-01 Cadila Healthcare Limited Angptl3 based vaccine for the treatment of liver disease
CN110596399B (zh) * 2019-08-29 2022-07-22 首都医科大学附属北京安贞医院 检测血管生成素样蛋白8含量的物质的应用
CN110694068A (zh) * 2019-11-06 2020-01-17 北京市心肺血管疾病研究所 一种抑制血管生成素样蛋白8的物质的应用
CA3166346A1 (fr) * 2020-01-22 2021-07-29 Jiangsu Hengrui Medicine Co., Ltd. Anticorps anti-angptl3 et son utilisation
IL316249A (en) * 2022-05-02 2024-12-01 Novo Nordisk As Novel anti-angptl3 antibodies suitable for high concentration compositions and subcutaneous administration
CN115947779B (zh) * 2022-08-10 2025-04-25 武汉安砥生物科技有限公司 针对人血管生成素样蛋白3的免疫原性肽段及其载体疫苗和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020035058A1 (en) * 1996-05-15 2002-03-21 The University Of Sheffield Isopentenyl pyrophosphate isomerase (IPI) and/or prenyl transferase inhibitors
US6172071B1 (en) 1998-07-30 2001-01-09 Hughes Institute Lipid-lowering quinazoline derivative
EP1151092B1 (fr) 1999-02-12 2008-12-31 President And Fellows Of Harvard College Inhibition de la formation des lesions atherosclereuses avec des acides nucléiques antisens d'afabp
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2008073300A2 (fr) 2006-12-08 2008-06-19 Lexicon Pharmaceuticals, Inc. Anticorps monoclonaux dirigés contre angptl3
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
EP2398476B1 (fr) 2009-02-23 2018-02-07 Nanorx, Inc. Nanoparticules de policosanol
CN102753186B (zh) * 2010-01-08 2016-09-14 Isis制药公司 血管生成素样3表达的调节
AR087329A1 (es) * 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
US20160002315A1 (en) 2013-03-14 2016-01-07 Uab Research Foundation Apolipoprotein mimetics and uses thereof
US10494442B2 (en) * 2013-06-07 2019-12-03 Sanofi Biotechnology Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
PT3087183T (pt) * 2013-12-24 2020-10-08 Ionis Pharmaceuticals Inc Modulação da expressão da proteína relacionada com angiopoietina 3
TW201713690A (zh) * 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途

Also Published As

Publication number Publication date
JP2019509271A (ja) 2019-04-04
IL260931A (en) 2018-09-20
JP7648335B2 (ja) 2025-03-18
EP3416684A1 (fr) 2018-12-26
CN108697797A (zh) 2018-10-23
JP2022177107A (ja) 2022-11-30
LT3416684T (lt) 2023-07-25
PL3416684T3 (pl) 2023-11-06
ZA201805058B (en) 2019-05-29
DK3416684T5 (da) 2024-09-16
MA44234B1 (fr) 2023-10-31
SMT202300219T1 (it) 2023-09-06
JP2024161504A (ja) 2024-11-19
HRP20230992T1 (hr) 2023-12-08
HUE062709T2 (hu) 2023-11-28
US20170233466A1 (en) 2017-08-17
EP4234013A3 (fr) 2023-11-08
FI3416684T3 (fi) 2023-07-31
KR102860143B1 (ko) 2025-09-16
AU2017219602B2 (en) 2023-10-12
AU2017219602A1 (en) 2018-08-23
AU2017219602C1 (en) 2024-05-09
EP4234013A2 (fr) 2023-08-30
US20200079841A1 (en) 2020-03-12
IL260931B2 (en) 2024-09-01
DK3416684T3 (da) 2023-07-31
MX2018009680A (es) 2018-09-10
PT3416684T (pt) 2023-07-04
IL260931B1 (en) 2024-05-01
EP3416684B1 (fr) 2023-06-21
US20220089711A1 (en) 2022-03-24
EA201891853A1 (ru) 2019-01-31
KR20180108840A (ko) 2018-10-04
RS64476B1 (sr) 2023-09-29
SI3416684T1 (sl) 2023-08-31
CA3014928A1 (fr) 2017-08-24
MD3416684T2 (ro) 2023-10-31
ES2951262T3 (es) 2023-10-19
WO2017142832A1 (fr) 2017-08-24

Similar Documents

Publication Publication Date Title
MA44234A (fr) Procédés de traitement ou de prévention de l'athérosclérose par administration d'un inhibiteur d'angptl3
EP3661691A4 (fr) Système de traitement laser d'une surface de tuyau
MA45192A (fr) Traitement d'association
MA46098A (fr) Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r
EP3600281A4 (fr) Traitement d'association pour le traitement ou la prévention de tumeurs
EP3328277A4 (fr) Systèmes, dispositifs et procédé permettant le traitement de l'arthrose
EP3374502A4 (fr) Procédés pour le traitement de dystrophies cornéennes
EP3390642A4 (fr) Compositions et procédés pour le traitement de rétinite pigmentaire 18 et de rétinite pigmentaire 13
EP3506944A4 (fr) Compositions et méthodes de traitement d'un cancer déficient en suppresseurs tumoraux
EP3341391A4 (fr) Compositions et procédés pour le traitement de la douleur
EP3324973A4 (fr) Systèmes et procédés pour le traitement de l' il avec un photosensibilisateur
EP3320093A4 (fr) Compositions et procédés d'identification, d'évaluation, de prévention et de traitement du cancer à l'aide d'isoformes de slncr
EP3448421A4 (fr) Procédés et compositions pour la prévention et le traitement d'adhérences chirurgicales
EP3349743A4 (fr) Procédés et compositions d'inhibition de l'interaction dcn1-ubc12
MA54925A (fr) Compositions pour le traitement de troubles acido-basiques
EP3445450A4 (fr) Méthode de traitement ou de prévention d'états pathologiques hépatiques
GB201611712D0 (en) Methods and compounds for the treatment or prevention of severe or persistent influenza
MA45226A (fr) Compositions et méthodes de traitement ou de prévention d'affections liées à l'oxalate
EP3471722A4 (fr) Composés et méthodes pour la prévention et/ou le traitement du cancer
EP3347032A4 (fr) Traitement de l'ascite
MA41490A (fr) Procédé de prévention ou de traitement de la perte auditive
MA46086A (fr) Schéma posologique pour le traitement de tumeurs solides
EP3710434A4 (fr) Compositions, procédés, systèmes et/ou kits de prévention et/ou de traitement de néoplasmes
EP3632431A4 (fr) Agent de prévention ou de traitement de l'atrophie cérébrale
EP3344650A4 (fr) Aav-epo pour le traitement d'animaux de compagnie